tiprankstipranks
Trending News
More News >
Cryo-Cell International Inc (CCEL)
:CCEL
Advertisement

Cryo-Cell International (CCEL) AI Stock Analysis

Compare
50 Followers

Top Page

CCEL

Cryo-Cell International

(NYSE MKT:CCEL)

Rating:49Neutral
Price Target:
$5.00
▲(0.00%Upside)
Cryo-Cell International's overall stock score is driven by significant financial and operational challenges. The company's financial instability is highlighted by negative equity and high operational costs, despite strong cash flow management. Technical analysis shows weak market momentum, and corporate events present additional risks, such as license termination and dividend reduction. The high dividend yield offers some appeal but is overshadowed by broader financial and strategic concerns.
Positive Factors
Business Model
Cryo-Cell's core business of processing and storing stem cells has high margins and mostly recurring revenue, contributing to its financial attractiveness.
Dividend Yield
The company maintains a high dividend yield of 18.1%, which is attractive to investors seeking regular income.
Financial Performance
Cryo-Cell International reported a strong EBITDA performance, demonstrating resilience despite a slight decline in overall revenue.
Negative Factors
Litigation
The ongoing arbitration against Duke University could potentially impact the company's financial position, with management believing damages could exceed $100M.
Litigation Costs
Higher expenses are expected due to litigation costs and Duke royalty expenses being accrued.
Revenue Growth
There is a decrease in new business processed by 18%, impacting overall growth.

Cryo-Cell International (CCEL) vs. SPDR S&P 500 ETF (SPY)

Cryo-Cell International Business Overview & Revenue Model

Company DescriptionCryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue stem cells worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.
How the Company Makes MoneyCryo-Cell International primarily generates revenue through the fees it charges for its cryopreservation services. The company collects an initial processing fee when customers enroll in its storage program for umbilical cord blood and tissue. In addition to this upfront charge, Cryo-Cell earns recurring revenue from annual storage fees paid by clients who maintain their stored specimens with the company. These long-term storage contracts contribute significantly to the company's financial stability. Furthermore, Cryo-Cell may also have partnerships with healthcare providers and hospitals that refer clients to its services, enhancing its market reach and customer base.

Cryo-Cell International Financial Statement Overview

Summary
Cryo-Cell International's financial performance shows a stable revenue base but significant profitability and balance sheet challenges. The income statement indicates high operational costs impacting net profit. The balance sheet is under pressure with negative equity, highlighting financial instability. However, the cash flow statement provides a silver lining with strong cash generation capabilities, suggesting potential for operational turnaround with improved cost management and strategic financial restructuring.
Income Statement
60
Neutral
The income statement shows stable revenue with slight growth over the years, but profitability margins are concerning. The TTM gross profit margin is robust at 76.2%, yet the net profit margin is very low at 0.8%, indicating high operational costs. EBIT and EBITDA margins are 11.9% and 6.9% respectively, which show operational challenges. Revenue growth is modest, but profitability issues suggest room for efficiency improvements.
Balance Sheet
40
Negative
The balance sheet reveals significant financial risks with negative stockholders' equity of -$15.56 million, highlighting insolvency concerns. The debt-to-equity ratio cannot be calculated due to negative equity, indicating a leveraged position. Total assets are declining, and the equity ratio is negative, emphasizing financial instability. Overall, the balance sheet suggests urgent need for capital restructuring.
Cash Flow
65
Positive
Cash flow analysis shows strong operating cash flow relative to net income, with a TTM operating cash flow of $6.26 million and a free cash flow of $5.67 million. The free cash flow growth is positive, reflecting effective cash management despite low net income. The company has managed to maintain positive free cash flow, providing some financial flexibility amidst profitability challenges.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue31.99M31.34M30.34M28.88M31.15M
Gross Profit24.04M22.90M21.54M19.90M21.49M
EBITDA1.42M-10.42M6.65M5.32M7.22M
Net Income402.10K-9.52M2.77M2.08M3.62M
Balance Sheet
Total Assets64.68M61.22M64.89M60.66M46.20M
Cash, Cash Equivalents and Short-Term Investments3.50M980.25K1.72M8.34M10.45M
Total Debt12.93M10.90M11.61M2.82M6.24M
Total Liabilities77.89M72.25M66.41M56.48M48.87M
Stockholders Equity-13.22M-11.03M-1.52M4.18M-2.67M
Cash Flow
Free Cash Flow3.61M1.28M-8.60M974.92K8.02M
Operating Cash Flow6.01M8.92M8.57M7.93M8.47M
Investing Cash Flow-4.88M-8.14M-15.28M-6.95M357.49K
Financing Cash Flow-979.12K-2.07M147.86K-3.07M-5.00M

Cryo-Cell International Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price5.00
Price Trends
50DMA
5.01
Negative
100DMA
5.37
Negative
200DMA
6.26
Negative
Market Momentum
MACD
-0.04
Negative
RSI
50.66
Neutral
STOCH
39.25
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCEL, the sentiment is Neutral. The current price of 5 is above the 20-day moving average (MA) of 4.95, below the 50-day MA of 5.01, and below the 200-day MA of 6.26, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 50.66 is Neutral, neither overbought nor oversold. The STOCH value of 39.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CCEL.

Cryo-Cell International Risk Analysis

Cryo-Cell International disclosed 39 risk factors in its most recent earnings report. Cryo-Cell International reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Cryo-Cell International Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
69
Neutral
$17.41M12.266.16%35.25%175.21%
57
Neutral
$52.25M-131.17%9.79%-47.01%
52
Neutral
$7.65B0.16-63.14%2.08%16.38%0.82%
51
Neutral
$144.69M12.68-0.21%-26.00%-103.18%
49
Neutral
$40.30M380.0093.38%8.00%1.10%98.13%
48
Neutral
$43.64M-951.52%-0.70%-2.38%
39
Underperform
$22.79M14.03%-29.82%-2.57%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CCEL
Cryo-Cell International
5.00
-2.24
-30.94%
AMS
American Shared Hospital Services
2.70
-0.33
-10.89%
CCM
Concord Medical Services
5.25
-1.25
-19.23%
MODV
ModivCare
3.04
-19.90
-86.75%
DCGO
DocGo
1.46
-2.19
-60.00%
PIII
P3 Health Partners
7.27
-24.01
-76.76%

Cryo-Cell International Corporate Events

Legal ProceedingsBusiness Operations and Strategy
Cryo-Cell Faces License Termination by Duke University
Negative
May 22, 2025

Cryo-Cell International, Inc. has received a notice of termination from Duke University regarding their Patent and Technology License Agreement, effective May 17, 2025. The termination is based on Duke’s claim that Cryo-Cell breached the agreement, following Cryo-Cell’s arbitration demand alleging fraudulent inducement and multiple breaches by Duke.

The most recent analyst rating on (CCEL) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Cryo-Cell International stock, see the CCEL Stock Forecast page.

Dividends
Cryo-Cell International Declares Reduced Quarterly Dividend
Negative
May 8, 2025

On May 7, 2025, Cryo-Cell International‘s Board of Directors declared a reduced quarterly cash dividend of $0.15 per share, reflecting the current economic environment and capital allocation alternatives. This decision, announced on May 8, 2025, may impact shareholder returns and indicates a cautious approach to financial management amid uncertain economic conditions.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 24, 2025